$CVR

CVI Maintained by UBS -- Price Target Raised to $53.00

UBS analyst Manav Gupta maintained a Neutral rating on CVR Energy (CVI) but raised the price target to $53.00 from $35.00. GuruFocus values CVI at $28.25, suggesting a 93.6% overvaluation at its current price of $54.69. The company operates in petroleum refining and nitrogen fertilizer industries, with a market cap of $5.5 billion. Analysts and insiders show mixed signals on the stock's future.

Original reporting
Published Oct 2, 2026, 7:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CVR
Neutral
medium confidence
Mentioned
$CVR
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$CVRNeutralMed
01

Why it matters

The target raise may attract some buying interest, but valuation concerns and high P/E suggest limited upside, keeping the stock near overvalued levels.

02

Market read

Analyst rating change provides fresh data for traders but is unlikely to trigger large price moves given existing overvaluation.

03

What to watch

Potential operational risks in refining and fertilizer segments and macro‑energy price volatility are not reflected in the target.

Relevance 6/10Novelty 6/10Timing: today

Background

The article summarizes UBS analyst Manav Gupta's rating update for CVR Energy, highlighting a new price target and valuation metrics.

Company-level read

Ticker impact

$CVRNeutralMedium confidence
Context

UBS raised CVR Energy's price target to $53 from $35 while maintaining a Neutral rating, a new analyst action disclosed today.

Expected impact

likely modest pressure as market weighs overvaluation against higher target

Evidence & confidence

Target increase signals optimism, yet the stock is deemed overvalued with a high P/E, limiting bullish impact.

Market effects

Energy sector peers may see slight re‑rating pressure as analysts reassess valuation benchmarks.

U.S. energy stocks could experience modest volatility in response to the rating change.

Limited; primarily affects CVR Energy and its immediate investor base.

Counterpoint

Despite the higher target, the stock remains significantly overvalued; a short position could be justified.

Key entities

  • CVR Energy Inc.

    U.S. listed energy company (ticker CVR) operating refineries and fertilizer plants.

  • UBS

    Investment bank providing the rating update.

Related articles

$PHOSMed

First Phosphate Targets Western LFP Supply Chain With Quebec Project

First Phosphate (NASDAQ:PHOS) is developing a phosphate project in Quebec to support LFP battery supply. The company reported a 378% increase in indicated resources, with a net present value of C$2.1B. It has secured government support and offtake agreements, aiming for production by 2030. The company is debt-free with $25M in cash and expects a two-year runway.

$HUMMed

Humana (HUM) Partners with BlackRock to Expand CenterWell Senior

Humana (HUM) announced a partnership with BlackRock (BLK) to manage 150 CenterWell Senior Primary Care clinics. BlackRock will acquire a $2.8B stake, taking majority ownership. The deal aims to expand operations and is expected to close in Q4 2026. Humana's stock is trading at $420.38, with a GF Value™ of $382.31, indicating a 10% overvaluation. The company has a GF Score™ of 83/100, reflecting strong growth and profitability.

$BNTXMedAI 8/10

BioNTech Cancer Shot Misses PFS Goal

BioNTech's BNT113 mRNA therapy failed to improve progression-free survival in a trial for HPV16-linked head and neck cancer. The study continues to test BNT113 with Keytruda for overall survival. BioNTech shares fell 6.1% premarket. The company faces competition from Moderna and Merck's recent melanoma trial success.